Darzalex Faspro 1800mg Injection

About

Darzalex Faspro 1800mg Injection is a subcutaneous formulation combining daratumumab, a CD38-directed cytolytic antibody, with hyaluronidase. It is specifically indicated for the treatment of multiple myeloma, a complex and aggressive plasma cell malignancy. Daratumumab targets CD38, a protein highly expressed on the surface of multiple myeloma cells, initiating various immune-mediated mechanisms to induce tumor cell death, including antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and antibody-dependent cellular phagocytosis (ADCP).

The co-formulated hyaluronidase enzyme facilitates the subcutaneous delivery of daratumumab by temporarily degrading hyaluronan in the extracellular matrix, allowing for a larger volume of drug to be absorbed more efficiently. This innovative formulation significantly reduces administration time compared to the intravenous daratumumab, enhancing patient convenience and potentially lowering healthcare resource utilization while maintaining the established efficacy and safety profile of daratumumab in treating multiple myeloma across various lines of therapy.

Uses

• Multiple myeloma (newly diagnosed)
• Relapsed/refractory multiple myeloma
• In combination with other therapies for multiple myeloma
• Amyloid light chain (AL) amyloidosis (off-label)

Directions For Use

Administer subcutaneously by a healthcare professional. Do not inject intravenously.

Benefits

• Reduced administration time
• Improved patient convenience
• Effective against multiple myeloma
• Various mechanisms of action
• Potential for combination therapy
• Subcutaneous delivery

Side Effects

• Infusion-related reactions
• Fatigue
• Nausea
• Diarrhea
• Upper respiratory tract infection
• Cough
• Dyspnea
• Peripheral neuropathy
• Constipation
• Pyrexia
• Headache
• Anemia
• Thrombocytopenia

Safety Measures

• Alcohol - No specific interaction known; use in moderation.
• Pregnancy - May cause fetal harm; avoid during pregnancy and use effective contraception.
• Breastfeeding - Unknown if excreted in human milk; advise against breastfeeding due to potential harm to infant.
• Liver - Use with caution; no specific dose adjustment guidelines for hepatic impairment.
• Kidney - Use with caution; no specific dose adjustment guidelines for renal impairment.
• Lung - Monitor for respiratory adverse reactions, including interstitial lung disease.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.